In the Boardroom - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

64 to 88 of 2175 results

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

Celgene’s Otezla is first oral therapy OKed by FDA for adults with active psoriatic arthritis

23-03-2014

The US Food and Drug Administration on Friday approved US biotech firm Celgene’s Otezla (apremilast),…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneNorth AmericaOtezlaRegulationUSA

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Novira names Christian Schade as chief executive officer

Novira names Christian Schade as chief executive officer

21-03-2014

Novira Therapeutics has announced the appointment of Christian Schade as chief executive officer, effective…

BoardroomPharmaceuticalUSA

US FDA eases clinical hold on Geron’s imetelstat

US FDA eases clinical hold on Geron’s imetelstat

21-03-2014

There was a touch of good news yesterday for Geron Corp, after the US Food and Drug Administrated partially…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

Takeda appoints Giles Platford as Head of Emerging Markets

Takeda appoints Giles Platford as Head of Emerging Markets

19-03-2014

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced the appointment of Giles…

BoardroomNorthern EuropePharmaceuticalTakeda Pharma GmbH

NeRRe Therapeutics announces appointment of Ian Nicholson as Chief Business Officer

NeRRe Therapeutics announces appointment of Ian Nicholson as Chief Business Officer

19-03-2014

UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor…

BoardroomNeRReTherapeuticsPharmaceuticalUK

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

UK budget unveils £55 million Cell Therapy Manufacturing Centre

UK budget unveils £55 million Cell Therapy Manufacturing Centre

19-03-2014

The UK’s annual budget speech by Chancellor of the Exchequer George Osborne today included the announcement…

BiotechnologyFinancialPoliticsResearchUK

Fortune 500 Executive joins Spherix as Vice President, Licensing

Fortune 500 Executive joins Spherix as Vice President, Licensing

19-03-2014

Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president…

BoardroomUSA

Pan-European survey calls for a shift in policy for biosimilars

Pan-European survey calls for a shift in policy for biosimilars

19-03-2014

This week, the Alliance for Safe Biologic Medicines (ASBM) disclosed the results of a survey of 470 European…

BiosimilarsBiotechnologyEuropeHealthcareRegulation

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

19-03-2014

Celgene UK and Ireland have announced the appointment of Rob Moore as the new Inflammation and Immunology…

BiotechnologyBoardroomCelgeneNorthern EuropeUK

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

FDA delays approval of Biogen Idec’s MS drug Plegridy

FDA delays approval of Biogen Idec’s MS drug Plegridy

18-03-2014

The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for…

Biogen IdecBiotechnologyNeurologicalNorth AmericaPlegridyRegulationUSA

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Australian regulator finds no definite melanoma link for natalizumab

Australian regulator finds no definite melanoma link for natalizumab

18-03-2014

Australia’s Therapeutic Goods Administration revealed today that it is monitoring reports of melanoma…

Asia-PacificAustraliaBiogen IdecBiotechnologyNatalizumabNeurologicalRegulationTysabri

ThromboGenics announces 2013 growth thanks to Jetrea sales

ThromboGenics announces 2013 growth thanks to Jetrea sales

18-03-2014

Belgium-based biopharma firm ThromboGenics has released its financial results for the full year 2013,…

BelgiumBiotechnologyFinancialJetreaOphthalmicsThromboGenics

Mike Sullivan appointed president of Avion Pharmaceuticals

Mike Sullivan appointed president of Avion Pharmaceuticals

18-03-2014

Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike…

Avion PharmaceuticalsBoardroomNovartisPharmaceuticalReproductiveSanofiTher-RxUSAWomen's Health

Formycon appoints US pharmaceuticals manager Bernhard Hampl to the advisor board

Formycon appoints US pharmaceuticals manager Bernhard Hampl to the advisor board

18-03-2014

Germany-based Formycon has appointed Bernhard Hampl, a top pharmaceuticals manager from the USA, to its…

BoardroomFormyconPharmaceuticalUSA

64 to 88 of 2175 results

Back to top